

# An SMS and IVR Intervention Improves Medication Adherence among Adults with T2DM and Low SES

Lyndsay A. Nelson, PhD

Center for Health Behavior and Health Education  
Division of Internal Medicine and Public Health  
Vanderbilt University Medical Center, Nashville TN

# Background

- Rx non-adherence
  - Common in type 2 diabetes (T2DM)<sup>1, 2</sup>
    - Especially among disadvantaged adults<sup>2, 3</sup>
  - Strong, independent predictor of suboptimal glycemic control, hospitalizations, premature death, and higher healthcare costs<sup>4, 5</sup>



- 1 Kirkman et al., 2015 *Diabetes Care*
- 2 Capoccia et al, 2016, *Annals of Intern Med*
- 3 Rolnick et al., 2013, *J Clin Med Res*
- 4 Aikens & Piette, 2013, *Diabetic Med*
- 5 Osborn et al., 2015, *J Clin Pharm Ther*

# Background



- Basic cell phone technology can improve adherence among disadvantaged adults<sup>8</sup>
- Over 90% of U.S. adults use cell phones<sup>6</sup>
  - Text messaging and voice communications are used equally across racial/ethnic and SES groups<sup>7</sup>

# Study Objective

- Disadvantaged adults with T2DM have suboptimal Rx adherence and glycemic control
- Cell phones give access to a wide range of adults

**We used a mixed-methods approach to evaluate a mHealth intervention to promote Rx adherence among diverse adults with T2DM**

# Messaging for Diabetes (MED)

- Tailors content and timing of text messages and IVR calls based on user needs and preferences
- Users receive 3 intervention elements:
  - A daily, tailored text message addressing barriers to adherence
  - A daily text message assessing adherence
  - A weekly IVR call providing adherence feedback, encouragement, and problem-solving opportunities


# Methods

- Sample and recruitment
  - 80 participants from a FQHC in Nashville, TN

Inclusion Criteria	Exclusion Criteria
At least 18 years of age	Pre-existing diagnosis of dementia
Diagnosed with T2DM	Auditory limitations
Prescribed diabetes Rx	Inability to see/respond to texts
Owned a cell phone with SMS texting capability	

# Methods

## Study Procedures



- **Matched each participant with two archival controls at baseline and compared A1c between groups at 3 months**

# Analyses

- Rx adherence – SDSCA-MS<sup>9, 10</sup>
  - Proportional odds logistic regression model
  - Spearman rank correlation coefficient
- Hemoglobin A1c – Lab value
  - Wilcoxon rank sum test
  - ANCOVA
- Experiences with MED
  - Inductive content analysis identified patterns and categories from follow- up interview responses.



# Results

<b>Participant Characteristics (N=80)</b>	
<b>Variable</b>	<b><i>M ± SD or n (%)</i></b>
Age, years	50.1 ± 10.5
Female	54 (68)
Non-White	55 (69)
Education, years	12.9 ± 2.3
Annual Income	
<10,000	29 (36)
10,000 – 20,000	27 (34)
>20,000	24 (30)
Insurance Status	
Private	14 (18)
Public	38 (48)
None	28 (35)
Insulin status	51 (64)
A1c	8.3 ± 2.0


# Results

## Rx Adherence

- Compared to baseline, adherence improved at one and two months, but not at three months.

Month	AOR	95%CI
1	3.88	1.79, 10.86
2	3.76	1.75, 17.44
3	1.49	0.66, 3.10

- Responding to text messages was marginally associated with improved adherence ( $\rho=0.23$ ,  $P=0.07$ ).



# Results

## A1c

- The MED and matched control group had similar stable A1c change at 3 months ( $P=0.40$ ).
- Using ANCOVA adjusted for baseline A1c and covariates, 3-month A1c did not differ between groups ( $P=0.42$ ).

# Follow-up Interview Results

Daily, tailored text message addressing barriers to adherence

- “Cell phone reminder alarms and pill boxes are great ways to help you remember when to take your meds.”

- **Why were these messages helpful?**

- Gave new ideas and information about taking Rx (31.7%)
- Encouraging; provided emotional support (26.7%)
- Reinforced importance of taking Rx (15%)

- **Suggestions for improving messages**

- More variety, outside of Rx-related content
- More cutting-edge news

# Follow-up Interview Results

Daily text messages assessing adherence

- “On Sat, 04/02, did you take ALL your diabetes meds? Reply with YES or NO.”
- **Did these messages help with taking Rx?**
  - Yes, extra reminder to take Rx (66.7%)
  - Yes, kept them on track/accountable (30%)
  - No, already had habit of taking Rx every day (15%)

# Follow-up Interview Results

Weekly IVR calls providing adherence feedback, encouragement, and problem-solving questions

- “This week you told us you took your diabetes medications as prescribed on 4 days. Last week you told us you took your diabetes medications as prescribed on 3 days.”
  - “Based on what you told us, you’ve taken your diabetes medications as prescribed on more days this week. Keep up the good work!”
  - “Describe a day when you were successful with taking your meds.”
  - “Describe a day when you were unsuccessful with taking your meds.”
- **Why were calls helpful or not helpful?**
    - More aware of how often taking Rx (31%)
    - Motivated to improve the following week (31%)
    - Not particularly helpful (23.7%)
      - Already knew how often taking Rx; Calls were bothersome; Adherence feedback not accurate; Could not call system back after midnight

# Discussion

- MED had a positive, short-term impact on Rx adherence
- A1c remained stable
- Overall, participants viewed MED favorably
  - Tailored messages provided information and support
  - Assessment messages served as a reminder
  - Text messages viewed more favorably than IVR calls

# Limitations and Future Directions

- Attrition
- Quasi-experimental study
- Limited generalizability
  
- Improving intervention to examine effects in a RCT
  - Using feedback to improve content and delivery of content
  - Excluding patients with optimal control



# Conclusions

- Leveraging technology available to the widest audience has far-reaching potential.
- Our findings provide preliminary support for using text messaging to improve Rx adherence among disadvantaged adults with T2DM.



# Acknowledgments

- Conflicts of Interest:
  - Nothing to disclose
- Funding:
  - This research was supported by a McKesson Foundation mHealth Award to Drs. Osborn and Mulvaney.
  - Dr. Osborn was supported by a career development award K01DK087894, the Vanderbilt Center for Diabetes Translational Research P30DK092986. Drs. Osborn and Nelson were both supported by R01DK100694.
- Contributors:
  - Chandra Y. Osborn, PhD. MPH; Shelagh A. Mulvaney, PhD; Tebeb Gebretsadik, MPH; Yun-Xian Ho, PhD; Kevin B. Johnson, MD, MS; Cecilia Quintero; Lindsay Mayberry, PhD; Lauren LeSturgeon, MPH

Thank You!

Questions?